stoxline Quote Chart Rank Option Currency Glossary
  
Acelyrin, Inc. (SLRN)
2.27  0 (0%)    05-21 16:00
Open: 2.27
High: 2.27
Volume: 4,059,159
  
Pre. Close: 2.27
Low: 2.27
Market Cap: 229(M)
Technical analysis
Short term     
Mid term     
Targets 6-month :  1-year : 
Resists First :  Second : 
Pivot price
Supports First :  Second : 
MAs MA(5) :  MA(20) : 
MA(100) :  MA(250) : 
MACD MACD :  Signal : 
%K %D K(14,3) :  D(3) : 
RSI RSI(14):
52-week High :  Low : 
Price, MAs and Bollinger Bands


Stock Price Prediction
If tomorrow: Open lower Open higher
High: - -
Low: - -
Close: - -
Company Description

Acelyrin, Inc. is a biopharmaceutical company focused on discovering, obtaining, and rapidly advancing the development and commercialization of innovative medical therapies. The firm's most advanced experimental drug is izokibep, a potent small protein therapeutic specifically designed to block IL-17A. This compound is currently undergoing Phase 3 clinical evaluations for its use in treating Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis. Additionally, izokibep is being assessed in Phase 2 clinical trials for Axial Spondyloarthritis. Beyond izokibep, Acelyrin is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets the insulin-like growth factor 1 receptor. Lonigutamab is in Phase 1 clinical studies for individuals with thyroid eye disease. Furthermore, the company has SLRN-517, a fully human IgG1 monoclonal antibody aimed at c-KIT, which is in the preclinical stage of development for the treatment of chronic urticaria. Founded in 2020, Acelyrin's corporate headquarters are located in Agoura Hills, California.

Headline News

Mon, 28 Apr 2025
Poison Pills Emerge Amid Tariff Uncertainty, Activism - The Deal Pipeline

Wed, 14 Aug 2024
Acelyrin deprioritises lead therapy despite Phase III win, fires 33% of staff - Clinical Trials Arena

Sat, 29 Jun 2024
Alumis (Nasdaq:ALMS) - Stock Analysis - Simply Wall St

Thu, 09 May 2024
Acelyrin’s founding CEO steps down, company scraps earnings call - Endpoints News

Tue, 12 Sep 2023
Acelyrin (NASDAQ: SLRN) drops 58% - nope, sadly, the drug don’t work - Dhaka Tribune

Mon, 22 May 2023
Acelyrin, Now Public, Focuses on Drug Pipeline - Los Angeles Business Journal

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 0 (M)
Held by Insiders (%)
Held by Institutions (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS
EPS Est Next Qtrly
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin %
Operating Margin %
Return on Assets (ttm) %
Return on Equity (ttm) %
Qtrly Rev. Growth %
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow
Stock Dividends
Dividend
Forward Dividend
Dividend Yield 0%
Dividend Pay Date
Ex-Dividend Date

StockChart iOS

Stoxline iOS

Alpha Bridge iOS

OptionCalc iOS

StockChart Android

Stoxline Android

Alpha Bridge Android

OptionCalc Android